Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma.
about
Bax is increased in the retina of diabetic subjects and is associated with pericyte apoptosis in vivo and in vitroSerine protease HtrA1 modulates chemotherapy-induced cytotoxicityMicrotubule-targeting drugs induce Bcl-2 phosphorylation and association with Pin1Microtubule-targeting drugs induce bcl-2 phosphorylation and association with Pin1Gene therapy for carcinoma of the breast: Pro-apoptotic gene therapyResistance and gain-of-resistance phenotypes in cancers harboring wild-type p53Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancerA sequential treatment regimen with melatonin and all-trans retinoic acid induces apoptosis in MCF-7 tumour cellsCHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancerMyocyte enhancer factor 2C as a neurogenic and antiapoptotic transcription factor in murine embryonic stem cellsProteomic profiling of hepatitis B virus-related hepatocellular carcinoma in China: a SELDI-TOF-MS study.Approaching solid tumor heterogeneity on a cellular basis by tissue proteomics using laser capture microdissection and biological mass spectrometryHaploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage.Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.Developmental regulation of Bcl-2 family protein expression in the involuting mammary gland.Amphipathic tail-anchoring peptide and Bcl-2 homology domain-3 (BH3) peptides from Bcl-2 family proteins induce apoptosis through different mechanismsDriving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis.Apoptosis is the essential target of selective pressure against p53, whereas loss of additional p53 functions facilitates carcinoma progression.Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer.The essential role of evasion from cell death in cancer.Recent advances in p53 research and cancer treatmentPrognostic Factors Including Proliferation Markers Ki-67, bax, and bcl-2 in Temporal Bone Paraganglioma.Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies.bax, but not bcl-2, influences the prognosis of human pancreatic cancerPrognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma.Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin.Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers.Immunodetection of apoptosis-regulating proteins in lymphomas from patients with and without human immunodeficiency virus infectionImmunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomachHypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progressionBAX enhances paclitaxel-induced apoptosis through a p53-independent pathway.bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis.Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimenChallenges toward personalized treatment of localized colorectal cancerBax expression is a candidate prognostic and predictive marker of colorectal cancer.Bax expression has prognostic significance that is enhanced when combined with AgNOR counts in glottic carcinomas.A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer.New insights into the kinetic resistance to anticancer agentsLoss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activityBaxΔ2 is a novel bax isoform unique to microsatellite unstable tumors
P2860
Q22253281-3F4E0267-AF5D-4831-B794-C729D479DE09Q24547477-4FDE9F3A-CE61-451D-B653-1BA9E6E02B89Q24551023-1DAB9FC3-AA48-4948-871E-2E1B09A3F9E4Q24551055-864D3A83-7C50-4C0A-B267-7BA77732B449Q24797919-8D2E5B0D-EB7B-4B53-8088-5D899742FACFQ27006998-B63C830A-AA50-4311-906A-C146854D477BQ28359548-D45A2BA5-A3BD-4EB0-BD53-C100019F90BCQ28379602-C0FDA05B-476A-461D-AA94-342B1B493EC4Q28473504-917E696A-0E04-4A85-9500-BCB43E8FDA97Q28591351-2845CA5C-A369-4EFB-9A8C-30A78261EB0DQ33369053-434CB3E4-29C9-4F43-B972-D3B028082512Q33418010-0EBCCB2E-B338-4A59-93D6-65CD05C42732Q33890906-8F6B2903-DA46-4CBD-8D12-DCD33B04AE77Q34323880-596E2EA7-1E23-4A47-ACC6-DFE721DFD8E7Q34629005-5791F520-0E14-4811-990F-5B63E21333FAQ34685438-C2B3F57D-BDD3-4E3A-A6EF-CF7EEAF3AC6FQ34785151-6AF9F0B9-4A77-4BD3-ABF0-6914B3E00A1DQ34803681-35476C73-F8E6-4F79-BED5-47921D22B661Q34908845-9A76CE36-2FD1-4635-AB37-54A3FD2EA893Q35083049-8E2AECF7-A4A0-4112-A986-0230D11D3859Q35099531-058AC0D9-D53B-4F80-BAF1-737EC2CB1C8EQ35160839-8A1461CB-C613-4326-A5C2-00F87BF74848Q35207960-13ECB7F7-17EB-4474-9276-8500690B118EQ35352240-2590B3A3-6B94-4BF8-8698-3FEE1915424EQ35588363-D1AD503D-EAFC-4CAA-BDE5-E1E60A2FC3ABQ35763574-6EDC267B-7655-4409-9F3B-704A162070A2Q35773657-93889253-1820-4F80-ACE1-431519EC566AQ35782275-0C4E261E-0854-432E-B5DF-EDF8A0E77AD2Q35782493-4382F4A0-0238-46B1-A94A-374149B38145Q35791446-1645C452-F726-4473-A4C3-1A5EC81E071CQ35944118-77114DD3-FB1B-4AA0-89B0-AB7050D223A1Q36040551-FDDC760E-8F9B-4B48-B2C4-6637EBB8528AQ36061780-944FE0F6-F4CC-400E-A5A8-F40BDF1FF25FQ36097087-DE1828B1-FBBE-42F5-81F3-35EC82665147Q36097096-51C1B9AC-2BB3-4BF7-A16D-531048AD2303Q36114804-5042AA06-DB6D-4A0E-8F15-B23ACB82F3F0Q36114964-AA534A85-CBF4-415B-8927-12B66A94372FQ36254839-E617D16E-A9CC-4E87-BEA0-2DC5121EF4B0Q36291775-50B57FA1-0768-47FE-B7F4-AC1FA75EF9F2Q36298500-92BD91FF-5148-4CD8-9B80-45D6B199C7E2
P2860
Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Reduced expression of proapopt ...... astatic breast adenocarcinoma.
@en
Reduced expression of proapopt ...... astatic breast adenocarcinoma.
@nl
type
label
Reduced expression of proapopt ...... astatic breast adenocarcinoma.
@en
Reduced expression of proapopt ...... astatic breast adenocarcinoma.
@nl
prefLabel
Reduced expression of proapopt ...... astatic breast adenocarcinoma.
@en
Reduced expression of proapopt ...... astatic breast adenocarcinoma.
@nl
P2093
P1433
P1476
Reduced expression of proapopt ...... astatic breast adenocarcinoma.
@en
P2093
Franssila K
Krajewska M
Krajewski S
Niskanen E
Nordling S
Wasenius VM
P304
P407
P577
1995-10-01T00:00:00Z